Plaintiff: Cadence Pharmaceuticals Inc. and SCR
Pharmatop
Defendant: Sandoz
Case Number:
3:13-cv-00278
Date Filed:
February 04, 2013
Court:California
Southern District Court
Patent Number
Current
Assignee[*]
|
Issue
Date
|
Expiration
Date[†]
|
Title
|
SCR Pharmatop
|
Feb
22, 2000
|
Aug 05, 2016
|
Stable
liquid paracetamol compositions, and method for preparing same
|
SCR Pharmatop
|
Jan
31, 2006
|
Jun 06, 2020
|
Method
for obtaining aqueous formulations of oxidation-sensitive active principles
|
Table information obtained from
Maxval’s Assignment
Database.
For the above mentioned patents
Cadence is the exclusive sub-licensee.
The Parties:
Cadence Pharmaceuticals develops
biopharmaceutical products. It focuses on acquiring, in-licensing, developing
and commercializing proprietary products, which are used in the hospital
setting. The company holds rights of OFIRMEV, a proprietary intravenous
formulation of acetaminophen for the management of pain and reduction of fever
in adults and children. The company was founded by Theodore R. Schroeder and
Cam L. Garner on May 26, 2004 and is headquartered in San Diego, CA.
Sandoz a division of the Novartis is a generic pharmaceutical
company with key product groups such as antibiotics, treatments for central
nervous system disorders, gastrointestinal medicines, cardiovascular
treatments, and hormone therapies. Sandoz develops, produces, and markets these
medicines along with pharmaceutical and biotechnological active substances and
anti-infectives.
As in complaint:
Defendant with the Abbreviated New Drug
Application (ANDA) No. 20-4052 seeks
approval of FDA to market a generic version of Cadence pharmaceutical product Ofirmev®, a
acetaminophen
injection as 10 mg/mL, 100 mL vials,
which is covered by the patents-in-suit.
Cadence is the current holder[‡] of the New Drug Application (NDA) no. 022450 for Ofirmev,
(source: Patent Marker) (see Fig. 1) with active ingredient as acetaminophen that is approved by FDA on November 02, 2010. Ofirmev is used to treat pain and
to reduce fever. Ofirmev is sometimes given with opioid (sometimes called
narcotic) pain medication to treat moderate to severe pain.
Other Cases Filed:
Plaintiff had recently filed 2 cases against
Fresenius Kabi USA (3:13-cv-00139 and 1:13-cv-00453) on January 17 and 18,
2013, which are pending.
If you are interested in knowing about the
case(s) filed by Cadence, please contact us.
To get alerts on cases filed, subscribe to our
Litigation Alerts.
[*] MaxVal offers Patent Assignment Alert service where subscribers
receive email alerts when assignments relating to target applications, patents
or entities of interest are recorded.
[†] Expected expiration date. Patent Term
Estimator is a free web-based tool that automatically calculates patent terms and
expiration dates for U.S. utility patents.
[‡] Patent Marker provides an online
environment where patentees can virtually mark products and search products for
patent-related information.
No comments:
Post a Comment